Pipeline Report: February 2021 | Articles

Patritumab Deruxtecan Under Exploration in Phase 2 HERTHENA-Lung01 Trial for EGFR+ NSCLC

April 1st 2021

The HER3-directed antibody-drug conjugate patritumab deruxtecan is under exploration in the treatment of patients with EGFR-mutated, metastatic or locally advanced non–small cell lung cancer who had previously received a TKI and platinum-based chemotherapy.

Camidanlumab Tesirine Under Investigation in Relapsed/Refractory Hodgkin Lymphoma

March 16th 2021

The safety and efficacy of the antibody-drug conjugate camidanlumab tesirine is under investigation in patients with relapsed/refractory Hodgkin lymphoma as part of a phase 2 clinical trial, which recently completed accrual.

Launch of ARANOTE Study Augments Development Program for Darolutamide in Prostate Cancer

March 3rd 2021

Darolutamide plus ADT will be evaluated versus ADT alone in patients with metastatic hormone-sensitive prostate cancer in the phase 3 ARANOTE study as part Bayer and Orion Corporation’s growing clinical development program for the oral AR inhibitor in prostate cancer.

Novel CDH6-Targeted ADC DS-6000 Enters the Pipeline in RCC and Ovarian Cancer

February 23rd 2021

February 23, 2021 - The first patient in a first-in-human phase 1 study has been dosed with DS-6000, a novel CDH6-directed antibody-drug conjugate.

Caribou and AbbVie Initiate Development Partnership for CAR T-Cell Products

February 23rd 2021

February 23, 2021 - AbbVie and Caribou Biosciences, Inc have entered into a collaboration and license agreement for the research and development of chimeric antigen receptory T-cell therapeutics.